Aurinia Pharmaceuticals Post Q3 Earnings: Assessing the Results
December 14, 2023
🌥️Trending News
Aurinia Pharmaceuticals ($NASDAQ:AUPH) is a publicly traded biopharmaceutical company based in Victoria, British Columbia, Canada. The company specializes in the development of innovative immunomodulating therapies for the treatment of autoimmune diseases. Aurinia’s primary focus is on its lead product, Voclosporin, which is being developed as a potential treatment for lupus nephritis (LN). This post will provide an assessment of Aurinia Pharmaceuticals’ Q3 earnings and discuss what they might mean for the company’s future prospects. This was mainly due to increased costs associated with the ongoing Phase 3 AURION clinical trial for Voclosporin. This strong financial performance reflects the company’s progress in developing Voclosporin as a potential treatment for LN and should help to ensure that Aurinia can continue to fund its research and development efforts going forward.
Looking ahead, Aurinia Pharmaceuticals is in a strong position to continue to develop Voclosporin and potentially launch it as a treatment for LN. With Phase 3 of the AURION trial currently underway and data expected in 2021, investors will be closely monitoring the company’s progress in the coming months as they anticipate the results of this important trial. Overall, Aurinia Pharmaceuticals’ Q3 earnings were largely positive and suggest that the company is on track to launch its flagship product, Voclosporin, as a potential treatment for lupus nephritis. With a strong balance sheet and continued progress in clinical trials, Aurinia has the potential to become a major player in the pharmaceutical industry and should be watched closely by investors in the months ahead.
Earnings
AURINIA PHARMACEUTICALS recently released their earnings report for FY2023 Q3 as of September 30 2021. According to the report, AURINIA PHARMACEUTICALS had a total revenue of 14.67M USD with a net loss of 50.26M USD. Compared to the same quarter last year, the total revenue for AURINIA PHARMACEUTICALS dropped by 73.7%.
However, a positive outlook can be seen when looking at AURINIA PHARMACEUTICALS’s total revenue over the last 3 years. From FY2021 Q3 to FY2023 Q3, total revenue reached from 14.67M USD to 54.52M USD, thus showing a significant increase. This indicates that AURINIA PHARMACEUTICALS is making progress even though the most recent quarterly earnings showed a decrease in total revenue.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Aurinia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 158.85 | -77.19 | -48.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aurinia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -37.32 | -3.47 | 1.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aurinia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 555.01 | 163.14 | 2.73 |
Key Ratios Snapshot
Some of the financial key ratios for Aurinia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 1007.3% | – | -50.3% |
| FCF Margin | ROE | ROA |
| -24.0% | -12.7% | -9.0% |
Market Price
Aurinia Pharmaceuticals recently reported their third quarter earnings which have been assessed by investors. On Thursday, AURINIA PHARMACEUTICALS stock opened at $8.8 and closed at the same price, representing a decrease of 0.9% from their last closing price. This is a slight drop compared to the earnings they experienced in the previous quarter. Despite the minor decrease, AURINIA PHARMACEUTICALS are continuing to demonstrate healthy growth in the market.
Investors are now focusing on how their fourth quarter results will shape up in order to better understand how their investments are performing. Analysts anticipate that AURINIA PHARMACEUTICALS will continue to experience growth in the long-term as the company continues to develop new treatments and expand its product range. With strong fundamentals and a robust financial position, AURINIA PHARMACEUTICALS are well-positioned to capitalize on the opportunities in the market and deliver impressive returns for its shareholders. Live Quote…
Analysis
At GoodWhale, we analyze AURINIA PHARMACEUTICALS‘s fundamentals to determine its overall financial health. According to our Star Chart, AURINIA PHARMACEUTICALS is strong in asset and growth, but weak in dividend and profitability. Our health score for AURINIA PHARMACEUTICALS is 3/10, which means that it is less likely to sustain future operations in times of crisis. We classify AURINIA PHARMACEUTICALS as a ‘cheetah’, a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who are looking for high growth potential and who are willing to take on more risk may be interested in such companies. However, investors should always be aware of the company’s financial health and ability to survive market downturns. More…
Peers
The company’s lead candidate, voclosporin, is a novel, potentially first-in-class immunomodulatory drug that is being investigated for the treatment of lupus nephritis and other autoimmune diseases. Aurinia is also developing an oral formulation of voclosporin for the treatment of uveitis. Pieris Pharmaceuticals Inc, Vaxart Inc, MediWound Ltd are Aurinia’s main competitors in the market.
– Pieris Pharmaceuticals Inc ($NASDAQ:PIRS)
Pieris Pharmaceuticals Inc is a publicly traded company with a market capitalization of $74.41M as of March 2022. The company has a Return on Equity of -89.14%. Pieris Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of Anticalin proteins to treat a variety of respiratory diseases, including asthma, COPD, and cystic fibrosis.
– Vaxart Inc ($NASDAQ:VXRT)
Vaxart Inc is a clinical-stage biotechnology company focused on the development and commercialization of oral recombinant vaccines. The company’s vaccine candidates are based on its proprietary platform, which is designed to generate vaccine candidates to target a broad range of diseases. Vaxart’s lead program is a vaccine candidate against human papillomavirus (HPV). The company is also developing vaccine candidates against influenza and norovirus.
– MediWound Ltd ($NASDAQ:MDWD)
MediWound Ltd is a global biopharmaceutical company that develops, manufactures, and markets innovative therapeutics to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. The company has a market capitalization of 56.19 million as of 2022 and a return on equity of 193.32%. MediWound was founded in 2000 and is headquartered in Yavne, Israel.
Summary
Aurinia Pharmaceuticals Inc. (AUPH) is an exciting biotech stock with a promising future. It has also acquired new product rights and invested in research and development to drive future growth. Additionally, AUPH is well-positioned to capitalize on potential opportunities to expand its product portfolio. With its strong financials and promising prospects, AUPH shares offer investors a good opportunity to benefit from its potential long-term growth.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
